Catalyzing innovative R&D for neglected tropical diseases, malaria, and tuberculosis
WIPO Re:Search is led by the World Intellectual Property Organization (WIPO) in partnership with BVGH and several leading pharmaceutical companies. Consortium membership includes academic and nonprofit research institutions, governmental and non-governmental organizations, and budding biotechnology companies committed to addressing the unmet medical needs of the developing world. Our 100+ Members represent 28 countries from six continents, including 22 African institutions. Download our Member list here.
The aim of the consortium is to accelerate the development of new drugs, vaccines, and diagnostics for neglected tropical diseases, malaria, and tuberculosis. BVGH creates partnerships that connect private industry’s assets and resources to qualified academic and nonprofit researchers with novel product discovery or development ideas.
BVGH’s leadership is critical to the Consortium’s success. As the Partnership Hub Administrator, BVGH proactively examines scientists’ current neglected disease research and proposes novel collaboration opportunities with other Members. BVGH also fields requests from researchers, identifies Member organizations able to fulfill these requests, and helps forge mutually beneficial collaborations with clearly-defined roles, responsibilities, and expectations.
Read the most recent news in the WIPO Re:Search Snapshot.
Featured Collaboration: GlaxoSmithKline & University of California, San Diego
Kinases are involved in key cellular processes and are chemically tractable drug targets. However, less than 5% of the human kinome has been explored with selective small molecule inhibitors. To demonstrate the enzymes’ therapeutic utilities, GlaxoSmithKline (GSK) has compiled two sets of kinase inhibitors, Published Kinase Inhibitor Set 1 (PKIS1) and Set 2 (PKIS2), and is sharing these sets with academic researchers to advance biological evaluation and pharmacological understanding of the unmapped human kinome.
Given the usefulness and versatility of these inhibitors, GSK is currently collaborating with over 100 researchers to explore the full use of the compounds. A few notable diseases being studied through WIPO Re:Search include tuberculosis, malaria, and schistosomiasis. Described below is one such collaboration.
Polo-like kinases (Plks) are important regulators of cell cycle progression and mitosis. In mammals there are five Plks (Plk 1-5). SmPlk1 and SmSak—homologous to Plk1 and Plk4 respectively—are expressed in the parasitic worm Schistosoma mansoni. Dr. Conor Caffrey of the Center for Discovery and Innovation in Parasitic Diseases (http://www.cdipd.org/) at the University of California, San Diego (UCSD) has evidence from whole-organism screens that specific inhibition of SmPlk1 by commercially available inhibitors of human Plk1 kills the helminth. To further the investigation of SmPlk1 as a potential target for disease intervention, BVGH connected UCSD and GSK. GSK agreed to provide Dr. Caffrey with PKIS1 and PKIS2. The sets, which contain 367 and 539 compounds respectively, include specific Plk inhibitors. The results of Dr. Caffrey’s screens will be released soon.
Note: The team of GSK scientists that developed PKIS1 and PKIS2 recently moved to the University of North Carolina (UNC), Chapel Hill (https://pharmacy.unc.edu/research/sgc-unc/). In order to further support the growing list of collaborations based on kinase inhibitor sharing, GSK licensed PKIS1 and PKIS2 to UNC Chapel Hill. Interested parties can reach out to the UNC team with questions about the kinase inhibitor sharing initiative by sending an e-mail to email@example.com.
If you are interested in becoming a member of the consortium or learning more, please email Katy Graef at firstname.lastname@example.org.